Logo image of NRBO

NEUROBO PHARMACEUTICALS INC (NRBO) Stock Fundamental Analysis

NASDAQ:NRBO - Nasdaq - US64132R4048 - Common Stock - Currency: USD

2.36  +0.01 (+0.43%)

Fundamental Rating

2

Overall NRBO gets a fundamental rating of 2 out of 10. We evaluated NRBO against 558 industry peers in the Biotechnology industry. NRBO scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. NRBO does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

NRBO had negative earnings in the past year.
In the past year NRBO has reported a negative cash flow from operations.
In the past 5 years NRBO always reported negative net income.
NRBO had a negative operating cash flow in each of the past 5 years.
NRBO Yearly Net Income VS EBIT VS OCF VS FCFNRBO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 -10M -20M -30M

1.2 Ratios

NRBO has a worse Return On Assets (-125.23%) than 80.60% of its industry peers.
NRBO has a Return On Equity of -214.10%. This is in the lower half of the industry: NRBO underperforms 68.78% of its industry peers.
Industry RankSector Rank
ROA -125.23%
ROE -214.1%
ROIC N/A
ROA(3y)-62.45%
ROA(5y)-121.04%
ROE(3y)-81.21%
ROE(5y)-165.85%
ROIC(3y)N/A
ROIC(5y)N/A
NRBO Yearly ROA, ROE, ROICNRBO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 200 -200 -400 -600 -800

1.3 Margins

NRBO does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
NRBO Yearly Profit, Operating, Gross MarginsNRBO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023

More info and screens

6

2. Health

2.1 Basic Checks

The number of shares outstanding for NRBO has been reduced compared to 1 year ago.
Compared to 5 years ago, NRBO has more shares outstanding
NRBO has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
NRBO Yearly Shares OutstandingNRBO Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 5M 10M 15M 20M 25M
NRBO Yearly Total Debt VS Total AssetsNRBO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M

2.2 Solvency

NRBO has an Altman-Z score of -10.54. This is a bad value and indicates that NRBO is not financially healthy and even has some risk of bankruptcy.
NRBO has a worse Altman-Z score (-10.54) than 75.31% of its industry peers.
NRBO has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -10.54
ROIC/WACCN/A
WACCN/A
NRBO Yearly LT Debt VS Equity VS FCFNRBO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 10M -10M 20M -20M

2.3 Liquidity

A Current Ratio of 2.41 indicates that NRBO has no problem at all paying its short term obligations.
With a Current ratio value of 2.41, NRBO is not doing good in the industry: 71.43% of the companies in the same industry are doing better.
NRBO has a Quick Ratio of 2.41. This indicates that NRBO is financially healthy and has no problem in meeting its short term obligations.
NRBO's Quick ratio of 2.41 is on the low side compared to the rest of the industry. NRBO is outperformed by 70.19% of its industry peers.
Industry RankSector Rank
Current Ratio 2.41
Quick Ratio 2.41
NRBO Yearly Current Assets VS Current LiabilitesNRBO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 62.98% over the past year.
EPS 1Y (TTM)62.98%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%23.61%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

NRBO is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 17.81% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-4.04%
EPS Next 2Y26.29%
EPS Next 3Y17.81%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
NRBO Yearly EPS VS EstimatesNRBO Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2019 2020 2022 2023 2024 2025 2026 -500 -1K -1.5K -2K -2.5K

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

NRBO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year NRBO is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
NRBO Price Earnings VS Forward Price EarningsNRBO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
NRBO Per share dataNRBO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -2 -4

4.3 Compensation for Growth

NRBO's earnings are expected to grow with 17.81% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y26.29%
EPS Next 3Y17.81%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for NRBO!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

NEUROBO PHARMACEUTICALS INC

NASDAQ:NRBO (11/27/2024, 8:56:43 PM)

2.36

+0.01 (+0.43%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-07 2024-11-07/bmo
Earnings (Next)N/A N/A
Inst Owners12.52%
Inst Owner Change0%
Ins Owners75.88%
Ins Owner Change0%
Market Cap20.34M
Analysts85
Price Target27.2 (1052.54%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-17.66%
Min EPS beat(2)-61.46%
Max EPS beat(2)26.13%
EPS beat(4)2
Avg EPS beat(4)-38.93%
Min EPS beat(4)-184.75%
Max EPS beat(4)64.34%
EPS beat(8)5
Avg EPS beat(8)-2.17%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)27%
EPS NQ rev (3m)26.04%
EPS NY rev (1m)8.67%
EPS NY rev (3m)8.67%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.57
P/tB 1.57
EV/EBITDA N/A
EPS(TTM)-6
EYN/A
EPS(NY)-1.59
Fwd EYN/A
FCF(TTM)-2.63
FCFYN/A
OCF(TTM)-2.63
OCFYN/A
SpS0
BVpS1.5
TBVpS1.5
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -125.23%
ROE -214.1%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-62.45%
ROA(5y)-121.04%
ROE(3y)-81.21%
ROE(5y)-165.85%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 85.71%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.41
Quick Ratio 2.41
Altman-Z -10.54
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)277.78%
Cap/Depr(5y)376.67%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)62.98%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%23.61%
EPS Next Y-4.04%
EPS Next 2Y26.29%
EPS Next 3Y17.81%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-132.24%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-77.26%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-77.12%
OCF growth 3YN/A
OCF growth 5YN/A